XBiotech Inc (XBIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XBiotech Inc (XBIT) has a cash flow conversion efficiency ratio of -0.164x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.95 Million) by net assets ($140.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of XBiotech Inc to measure how many days the company can operate on defensive assets alone.
XBiotech Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how XBiotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
XBiotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XBiotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Melrose Industries PLC
LSE:MRO
|
0.003x |
|
Vortex Consolidated Bhd
KLSE:0060
|
-0.013x |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
-0.047x |
|
BioHarvest Sciences Inc. Common Stock
NASDAQ:BHST
|
-0.068x |
|
St. James's Place plc
LSE:STJ
|
-0.056x |
|
Transat AT Inc
TO:TRZ
|
-0.440x |
|
Altenergy Acquisition Corp
NASDAQ:AEAE
|
0.017x |
|
Hyundai C&F Inc
KO:227840
|
0.042x |
Annual Cash Flow Conversion Efficiency for XBiotech Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of XBiotech Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see XBiotech Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $140.35 Million | $-39.92 Million | -0.284x | -67.43% |
| 2024-12-31 | $182.27 Million | $-30.96 Million | -0.170x | -98.54% |
| 2023-12-31 | $218.85 Million | $-18.73 Million | -0.086x | -38.76% |
| 2022-12-31 | $240.40 Million | $-14.82 Million | -0.062x | -123.92% |
| 2021-12-31 | $269.38 Million | $69.44 Million | 0.258x | +237.95% |
| 2020-12-31 | $348.64 Million | $-65.15 Million | -0.187x | -672.86% |
| 2019-12-31 | $755.63 Million | $-18.27 Million | -0.024x | +93.95% |
| 2018-12-31 | $41.40 Million | $-16.54 Million | -0.399x | +28.58% |
| 2017-12-31 | $60.16 Million | $-33.65 Million | -0.559x | +28.21% |
| 2016-12-31 | $59.06 Million | $-46.02 Million | -0.779x | -141.03% |
| 2015-12-31 | $103.05 Million | $-33.31 Million | -0.323x | -63.08% |
| 2014-12-31 | $59.03 Million | $-11.70 Million | -0.198x | +77.24% |
| 2013-12-31 | $10.23 Million | $-8.91 Million | -0.871x | +44.81% |
| 2012-12-31 | $7.37 Million | $-11.63 Million | -1.578x | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more